Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Start Date
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1202)
•••
Comment by Duster340on Jan 19, 2024 1:40pm
142 Views
Post# 35836256

RE:RE:RE:RE:RE:RE:RE:RE:Start Date

RE:RE:RE:RE:RE:RE:RE:RE:Start Date
Inthepez wrote:

Believe what you want dimwit, we're not all pathetic traders like you, wasting our time on boarders for penny flipping. Don't be jealous I'm sitting on a hefty green bag.

Maybe you should one of your other accounts to spread fear lol! How many handles did you have at your peak? Lol. Are you still using your Czechcashings account? I miss the dumpster that really worked hard at his entertaining trolling. 

that angry negative outburst confirms to me that you indeed sold at a loss, you should have held and loaded up when the stock was in the 40's and then sold above $1.10  on the first run up. you would have been able to get out with a smaller loss. chequecashing was davgro/pez?  he got left behind when the stock quickly moved up right after he said it was going nowhere and is a tax loss candidate.  lol 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities